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Abstract
Background
Alzheimer’s disease is a neurodegenerative syndrome characterized by multiple dimen-
sions including cognitive decline, decreased daily functioning and psychiatric symptoms.
This systematic review aims to investigate the relation between somatic comorbidity burden
and progression in late-onset Alzheimer’s disease (LOAD).
Methods
We searched four databases for observational studies that examined cross-sectional or lon-
gitudinal associations of cognitive or functional or neuropsychiatric outcomes with comorbid-
ity in individuals with LOAD. From the 7966 articles identified originally, 11 studies were
included in this review. The Newcastle-Ottawa quality assessment was used. The large vari-
ation in progression measures, comorbidity indexes and study designs hampered the ability
to perform a meta-analysis. This review was registered with PROSPERO under DIO:
10.15124/CRD42015027046.
Results
Nine studies indicated that comorbidity burden was associated with deterioration in at least
one of the three dimensions of LOAD examined. Seven out of ten studies investigating cog-
nition found comorbidities to be related to decreased cognitive performance. Five out of the
seven studies investigating daily functioning showed an association between comorbidity
burden and decreased daily functioning. Neuropsychiatric symptoms (NPS) increased with
increasing comorbidity burden in two out of three studies investigating NPS. Associations
were predominantly found in studies analyzing the association cross-sectionally, in a time-
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varying manner or across short follow-up (2 years). Rarely baseline comorbidity burden
appeared to be associated with outcomes in studies analyzing progression over longer fol-
low-up periods (>2 years).
Conclusion
This review provides evidence of an association between somatic comorbidities and multi-
faceted LOAD progression. Given that time-varying comorbidity burden, but much less so
baseline comorbidity burden, was associated with the three dimensions prospectively, this
relationship cannot be reduced to a simple cause-effect relation and is more likely to be
dynamic. Therefore, both future studies and clinical practice may benefit from regarding
comorbidity as a modifiable factor with a possibly fluctuating influence on LOAD.
1. Introduction
Dementia is typically defined as a clinical syndrome of cognitive decline that is sufficiently severe
to interfere with social or occupational functioning [1]. It is an umbrella term for a group of cog-
nitive disorders characterized by progressive decline in cognitive function interfering with inde-
pendently carrying out activities of daily life due to brain damage or disease, but not related to
delirium or depression [2]. Alzheimer’s disease (AD) is the most common cause of dementia in
late life and accounts for 50–70% of the cases [3]. AD is a neurodegenerative syndrome charac-
terized by multidimensional progression consisting of three core dimensions: cognitive, func-
tional and psychiatric symptoms [4], with functional symptoms being defined as a decreased
ability to independently perform daily life activities. Its prevalence is increasing rapidly due to
aging of most societies, though incidence seems to decline in people with high educational levels
in high income countries [5]. This review focuses specifically on late-onset Alzheimer’s disease
(LOAD), which is defined as AD with an onset after 65 years of age. LOAD is more prevalent
and generally has a more slowly progressing course as compared to early-onset AD [6].
Currently it is impossible to provide patients and their families with a reliable prediction of
the course of their disease, as there is substantial variability in rates of decline among individu-
als with LOAD [7]. Knowing which factors are associated with decline would be useful for
understanding and slowing disease progression, as well as for individual prognosis [8]. Poten-
tially influential factors are comorbidities. Comorbidity is defined as any additional co-existing
ailment in a patient with a particular index disease [9], in this case LOAD. It has been shown
that comorbidities are more prevalent among individuals with LOAD as compared to demo-
graphically-matched controls [10]. In addition, a review indicated that comorbidity contrib-
utes to decline in LOAD [11]. However, it is unclear exactly how comorbidities affect the
separate facets of LOAD, since many studies merely report relations between comorbidity and
one dimension of LOAD, despite the multifaceted nature of the syndrome [4]. In order to pro-
vide a multidimensional overview, this review investigates whether there is evidence for an
association between comorbid disease burden and cognitive, functional and psychiatric symp-
toms in individuals with LOAD, both cross-sectionally and longitudinally.
2. Methods
The articles were identified using the electronic databases Medline, EMBASE, PsycINFO and
Cochrane updated until January 2016. Comprehensive search strategies were developed sepa-
rately for each of the four databases (S1, S2, S3 and S4 Appendixes). The keywords “Alzheimer”
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and “observational studies” and “progression” and “comorbidity” were used in subsequent com-
binations with either “cognition” or “daily functioning” or “behavior disorders”, along with their
synonyms. In order to meet the inclusion criteria, articles had to examine cognitive or functional
or neuropsychiatric outcomes in relation to comorbidity in individuals diagnosed with LOAD
(age 65 or over at onset). No restriction for years of publication was used. In order to summarize
all available evidence on the association between comorbid disease burden and dementia symp-
toms, both longitudinal and cross-sectional studies were included. Since this review addresses
somatic comorbid disease burden in general, the influence of individual diseases is beyond the
scope of this study. The protocol of this review was registered with PROSPERO and can be
accessed through DIO: 10.15124/CRD42015027046.
The database searches yielded 7954 articles and 12 papers were identified by other means:
the snowball method yielded seven articles and an additional search for grey literature in the
online databases OpenGrey, Open DOAR and Google Scholar resulted in the identification of
five new articles. From the total of 7966 articles originally identified, 4905 duplicates were
excluded. The title and abstract of the 3061 articles were independently screened by two
reviewers (L.R.V., M.L.H.) and 3014 articles were excluded for not meeting the inclusion crite-
ria. After that, another 36 studies were excluded based on full text assessment which was per-
formed in duplicate as well (L.R.V., M.L.H.). Discrepancies between the two reviewers were
resolved by a third reviewer (R.J.F.M.). The remaining 11 articles were critically appraised,
again by two independent reviewers (L.R.V., M.L.H.), using the Newcastle-Ottawa quality
assessment for cohort studies [12] which assesses the selection of participants, methods to con-
trol for confounding and assessment of the outcome. For cross-sectional studies, an adapted
version of the scale was used in which questions regarding follow-up were left out. An over-
view of the selection process is provided in Fig 1. The first two authors of this review (L.R.V.
and M.L.H.) did not (co)author any of the included studies. J.S.L. is first author of one of the
included studies [13], as is R.J.F.M. [14]. Moreover, A.M., J.S.L., M.G.M.O.R. and R.J.F.M. all
co-authored one of the included studies [14–16].
3. Results
Out of the 47 studies deemed eligible after screening, 12 did not examine any LOAD dimen-
sion as an outcome, 19 did not study the influence of comorbid disease burden and 5 did not
focus on LOAD. The remaining 11 articles included in this review were published between
1998 and 2015 [13–23]. An overview of these studies is provided in Table 1. The diagnosis cri-
teria used for LOAD were NINCDS-ADRDA (National Institute of Neurological and Commu-
nicative Disorders and Stroke; Alzheimer’s Disease and Related Disorders Association) [2]
and/or DSM (Diagnostic and Statistical Manual of Mental Disorders) [24]. Comorbid disease
burden was measured using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) [25],
Charlson Comorbidity Index (CCI) [26], General Medical Health Rating (GMHR) [15] and
some studies counted the comorbidities based on hospital records, physical examination and/
or patient/caregiver report. Although the comorbidity measures differed across studies, most
studies used a personal approach with either an interview or medical examination by a
physician.
Five studies were cross-sectional and six were longitudinal studies with maximum follow-
up ranging from 1 to 12 years. The overall mean age of the participants across studies was 80.3
years (range: 69.9–86.0). After quality assessment, only one study was deemed to be of low
quality with a score below 50% due to lack of correction for confounding and unrepresentative
sampling [19]. Adjustment for baseline age was unclear in two studies [15, 19]. Adjustment for
education was lacking or unclear in five studies examining cognition [16, 17, 19–21].
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Adjustment for baseline symptoms of interest was unclear in one out of six longitudinal stud-
ies [19]. An overview of the quality assessment of all included studies is provided in S5
Appendix.
Nine studies indicated that symptoms were worse in at least one of the three dimensions of
LOAD in individuals with increased comorbid disease burden, while two studies failed to find
an association. The following sections will address the results for three different dimensions of
LOAD.
3.1 Studies on global and cognitive abilities
Four cross-sectional and six longitudinal studies examined cognitive outcomes. An overview of
these studies, including their measurement scales and results is provided in Table 2. Eight stud-
ies used the Mini-Mental State Examination (MMSE) [27] to measure cognition, one used the
Global Deterioration Scale (GDS) [28] and one used a composite score of neuropsychological
tests [16]. The presence of comorbidities was related to decreased cognitive abilities in seven out
of the ten studies examining cognition. Three of these were cross-sectional and four were longi-
tudinal studies. In one of the longitudinal studies only time-varying comorbidity burden, not
time-invariant baseline comorbidity, was associated with decreased cognitive abilities (Table 2).
3.2 Studies on daily functioning
Four cross-sectional and three longitudinal studies examined daily functioning. These studies
are summarized in Table 3. Functional impairment was measured using (instrumental)
Fig 1. Prisma flow diagram.
https://doi.org/10.1371/journal.pone.0177044.g001
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Table 1. Description of all selected studies.
Author (year) Participants Cohort Study design Comorbidity measure Statistical analysis
Mean age±SD
(yr)
Setting Measurement
interval*
Data source
Lyketsos et al.
(1999)
N = 344 Clinical cohort, Cross-sectional General Medical Health
Rating
Pearson’s correlations
76.5±NA Baltimore, U.S.A. NA Independent assessment
by physician
Tekin et al.
(2001)
N = 143 Clinical cohort Cross-sectional Cumulative Illness Rating
Scale for Geriatrics
Pearson’s correlations and stepwise linear
regression with baseline covariates
76.5±7.8 Los Angeles, U.S.
A.
NA NA
Doraiswamy
et al. (2002)
N = 679 Mixed cohort** Cross-sectional Cumulative Illness Rating
Scale for Geriatrics
General Linear Model
80.7±NA 13 sites in 9 states
of the U.S.A.
NA Medical history and
physical examination
Formiga et al.
(2009)
N = 289 Clinical cohort Cross-sectional Charlson Comorbidity
Index
Logistic regression with baseline covariates
81.0±6.0 Barcelona, Spain NA Interview with patient/
caregiver and medical
records
Oosterveld et al.
(2014)
N = 213 Clinical cohort Cross-sectional Cumulative Illness Rating
Scale for Geriatrics
Pearson’s correlation and linear regression
with baseline covariates
75.0±10.0 3 sites in the
Netherlands
NA Medical examination by
physician
Aguero-Torres
et al. (1998)
N = 46 Population-based
cohort
Longitudinal Presence of chronic
condition (yes/no)
Linear regression for annual rate of change
with baseline covariates
86.0±5.6 Stockholm,
Sweden
3 years Informant interview
Boksay et al.
(2005)
N = 40 Clinical cohort Longitudinal Comorbidity count NA
69.9±3.2 New York, U.S.A. 4 years NA
Solomon et al.
(2011)
N = 102 Clinical cohort Longitudinal Cumulative Illness Rating
Scale for Geriatrics
Ordinal logistic regression for categories of
decline based on annual rate of change with
baseline covariates75.4±8.2 Bucharest,
Romania
2 years Medical records and
reports of patients/
caregivers
Leoutsakos et al.
(2012)
N = 230 Population-based
cohort
Longitudinal General Medical Health
Rating
Quadratic mixed models with random effects
for intercept and time including both baseline
and time-varying covariates85.9±6.3 Utah, U.S.A. 6 months (time-
varying)
11 years (time-
invariant)
Interview with patient and
caregiver and medical
records
Melis et al. (2013) N = 251 Population-based
cohort
Longitudinal Presence of 0, 1 or2
chronic conditions
Quadratic mixed models with baseline
covariates and random effects for intercept
and time85.5±4.5 Stockholm,
Sweden
3–12 years Stockholm Inpatient
Register
Aubert et al.
(2015)
N = 170 Clinical cohort Longitudinal Charlson Comorbidity
Index
Logistic regression with baseline covariates
83.3±5.4 Nantes, France 1 year NA
* = Time between comorbidity measurement and analyzed progression.
** = clinical, retirement and nursing home population.
N = number of participants included in the analysis.
NA = information not available.
https://doi.org/10.1371/journal.pone.0177044.t001
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Activities of Daily Living ((i)ADL) [29] in four studies, the Clinical Dementia Rating Scale
(CDR) [30] in one study, Health Utilities Index subscales [31] in one study and the Psychoger-
iatric Dependency Rating Scale (PGDRS) [32] in one last study. Five out of the seven studies
examining daily functioning found comorbidities to be related to lower functional abilities.
Three of these were cross-sectional and two were longitudinal. In one of the longitudinal stud-
ies only time-varying comorbidity burden, not time-invariant baseline comorbidity burden,
was associated with functional decline [13]. In the longitudinal study conducted by Melis et al.
(2013) also a cross-sectional association between baseline comorbidity burden and baseline
functional status was found [33]. The two smallest studies (one longitudinal, one cross-sec-
tional) did not find an association [17, 23].
3.3 Studies on neuropsychiatric symptoms
As shown in Table 4, all three studies examining neuropsychiatric symptoms (NPS) used the
Neuropsychiatric Inventory (NPI) [34]. Two studies were cross-sectional and one was longitu-
dinal. Two studies (one cross-sectional, one longitudinal) found comorbidities to be related to
increased NPS. In the one longitudinal study, only time-varying comorbidity burden, not
Table 2. Description of studies on global and cognitive abilities.
Author (year) Cognitive measure Study design Estimate (SE) ** Results
Measurement
interval*
Tekin et al.
(2001)
Mini Mental State
Examination
Cross-sectional NA Cumulative Illness Rating Scale for Geriatrics was not related to
cognitive statusNA
Doraiswamy et al.
(2002)
Mini Mental State
Examination
Cross-sectional R2 = 0.34,
p<0.0001
Higher Cumulative Illness Rating Scale for Geriatrics was
related to lower cognitive statusNA
Formiga et al.
(2009)
Mini Mental State
Examination
Cross-sectional Mean Δ = 0.2
(0.11), p = 0.02
Higher Charlson Comorbidity Index was related to lower
cognitive statusNA
Oosterveld et al.
(2014)
Neuropsychological
assessment
Cross-sectional r = −0.19, p<0.01 Higher Cumulative Illness Rating Scale for Geriatrics was
related to poorer cognitive statusNA
Aguero-Torres
et al. (1998)
Mini Mental State
Examination
Longitudinal b = -0.25 (0.64),
p = 0.694
The presence of a chronic condition was not related to changes
in cognition3 years
Boksay et al.
(2005)
Global Deterioration
Scale
Longitudinal Mean Δ = 2.1
(1.04), p<0.05
The presence of a higher number of comorbidities was related
to a faster decline in cognition4 years
Solomon et al.
(2011)
Mini Mental State
Examination
Longitudinal b = 0.01, p = 0.02 Higher Cumulative Illness Rating Scale for Geriatrics was
related to faster decline in cognition2 years
Leoutsakos et al.
(2012)
Mini Mental State
Examination
Longitudinal β = −1.07 (0.42),
p = 0.01
Lower General Medical Health Rating was related to a
decreased cognitive abilities when analyzing it as a time-varying
covariate, but not when using it as a time invariant baseline
covariate
6 months (time-
varying)
11 years (time-
invariant)
β = 0.23 (0.46),
p = 0.61
Melis et al.
(2013)
Mini Mental State
Examination
Longitudinal b = -0.27, p = 0.17 The presence of either 0, 1 or2 comorbidities was not related
to cognition cross-sectionally nor longitudinally.3–12 years
Aubert et al.
(2015)
Mini Mental State
Examination
Longitudinal OR = 1.30, CI:
1.02–1.65, p = 0.03
Higher Charlson Comorbidity Index was related to faster decline
in cognition1 year
NA = Not available. SE = Standard Error. CI = 95% Confidence Interval.
* Time between comorbidity measurement and analyzed progression.
** For mixed models the interaction with the linear slope is reported.
https://doi.org/10.1371/journal.pone.0177044.t002
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time-invariant baseline comorbidity burden, was associated with more NPS. One cross-sec-
tional study found no association [17].
Table 3. Description of studies on daily functioning.
Author (year) Daily functioning
measure
Study design Estimate (SE) ** Results
Measurement
interval*
Lyketsos et al.
(1999)
Psychogeriatric
Dependency Rating Scale
Cross-sectional β = -4.1 (0.68),
p = 0.001
Lower General Medical Health Rating was related to
increased functional impairmentNA
Tekin et al.
(2001)
(instrumental) Activities of
Daily Living
Cross-sectional r = 0.10, p = 0.991 Cumulative Illness Rating Scale for Geriatrics was not related
to functioningNA
Doraiswamy
et al. (2002)
Subscale for self-care of
the Health Utilities Index
Cross-sectional R2 = 0.47, p<0.0001 Higher Cumulative Illness Rating Scale for Geriatrics was
related to greater functional impairmentNA
Oosterveld et al.
(2014)
(instrumental)
Activities of Daily Living
Cross-sectional r = −0.37, p<0.001 Higher Cumulative Illness Rating Scale for Geriatrics was
related to lower functional statusNA
Solomon et al.
(2011)
(instrumental) Activities of
Daily Living
Longitudinal OR = 2.7, CI: 0.7–
9.6
Higher Cumulative Illness Rating Scale for Geriatrics tended
to be related to increased decline in functioning, but this was
not significant
2 years
Leoutsakos
et al. (2012)
Clinical Dementia Rating
sum of boxes
Longitudinal β = 1.79 (0.34),
p<0.001
Lower General Medical Health Rating was related to
decreased functioning when analyzing it as a time-varying
covariate, but not when using it as a time invariant baseline
covariate
6 months (time-
varying)
11 years (time-
invariant)
β = −0.51 (0.34),
p = 0.13
Melis et al.
(2013)
Activities of Daily Living Longitudinal b = 0.34, p = 0.006 Presence of2 chronic conditions at baseline was cross-
sectionally related to lower baseline functional status and
also longitudinally to faster decline in functioning
3–12 years
NA = Not available. SE = Standard Error. CI = 95% Confidence Interval.
* Time between comorbidity measurement and analyzed progression.
** For mixed models the interaction with the linear slope is reported.
https://doi.org/10.1371/journal.pone.0177044.t003
Table 4. Description of studies on neuropsychiatric symptoms.
Author (year) Neuropsychiatric
measure
Study design Estimate (SE) ** Results
Measurement
interval*
Tekin et al.
(2001)
Neuropsychiatric
Inventory
Cross-sectional R = 0.21, p<0.05 Cumulative Illness Rating Scale for Geriatrics was not related to
neuropsychiatric symptomsNA
Oosterveld et al.
(2014)
Neuropsychiatric
Inventory
Cross-sectional R = 0.20, p<0.001 Higher Cumulative Illness Rating Scale for Geriatrics was related to
more neuropsychiatric symptomsNA
Leoutsakos
et al. (2012)
Neuropsychiatric
Inventory
Longitudinal 4.57 (1.80),
p = 0.01
Lower General Medical Health Rating was related to more
neuropsychiatric symptoms when analyzing it as a time-varying
covariate, but not when using it as a time invariant baseline covariate
6 months (time-
varying)
11 years (time-
invariant)
0.93 (1.05),
p = 0.38
NA = Not available. SE = Standard Error.
* Time between comorbidity measurement and analyzed progression.
** For mixed models the interaction with the linear slope is reported.
https://doi.org/10.1371/journal.pone.0177044.t004
Comorbidity and progression of late onset Alzheimer’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0177044 May 4, 2017 7 / 15
4. Discussion
4.1 Discussion of the current scientific evidence
Although the total evidence available for this review was limited, the main finding was that
increased somatic comorbid disease burden was associated with increased cognitive, func-
tional and neuropsychiatric symptoms in LOAD. Nine studies showed an association between
comorbid disease burden and LOAD symptoms, while only two studies found no association.
Primarily cross-sectional associations were found between comorbidity burden and the three
dimensions of LOAD. In the prospective studies, evidence for longitudinal associations
between baseline comorbidity burden and LOAD progression was inconsistent. Only three
studies examined all dimensions of LOAD simultaneously and two of these found associations
between comorbidity burden and all dimensions of LOAD [13, 16]. The third study by Tekin
et al. was cross-sectional and did not find any associations at all [17]. It was argued that the
associations were possibly obscured by the relatively low levels of comorbidity (mean±SD
CIRS-G: 5.8±3.0) and the young age (mean±SD: 76.5±7.8 years) of the study population. Only
one study evaluated time-varying associations and found all three dimensions to be associated
with time-varying comorbidity burden.
Seven out of ten studies examining cognitive abilities found a significant association
between increased comorbid disease burden and lower cognitive abilities. Of the three studies
which found no association, two were longitudinal and conducted in the same cohort [14, 22].
The third was the study by Tekin et al. (2001) mentioned previously [17]. Five out of seven
studies examining daily functioning found decreased functional status to be associated with
comorbid disease burden. The two negative studies were the study by Tekin et al. (2001) and
the smallest study on daily functioning by Solomon et al., which detected a non-significant
trend [17, 23]. Two out of three studies examining NPS found comorbidities to be related to
increased NPS. The negative study once again being the study by Tekin et al. (2001) [17].
The overall quality of the available evidence was rated as high according to the Newcastle-
Ottawa quality assessment (S5 Appendix), with the exception of one study of which the results
should be interpreted with caution [19]. It should be noted that this assessment does not dis-
tinguish between longitudinal and cross-sectional studies and that 5 out of the 11 studies in
this review were cross-sectional. The (reporting of) adjustment for confounders was found to
be inconsistent across studies and although most studies adjusted for age, the correction for
education was far less common. It is worth mentioning that the quality assessment does not
assess the studies’ sample size (Table 1) and although it takes follow-up rate at the end of the
study into account, the length of the study is ignored, while these two things are clearly related.
Altogether, the majority of the studies in this review suggest that comorbidity contributes
to a (more rapid) worsening of symptoms in LOAD, which is in accordance with a broader
conceptualization of LOAD as the consequence of a dynamic interaction of disease-related
and individual factors [35]. However, the association between comorbidity burden and LOAD
progression cannot be reduced to a linear causal relation where exposures to higher levels of
comorbidity burden are linked prospectively to dementia outcomes. Rather their relation is
more complex and dynamic. We will expand on this in the next paragraph.
4.2 Observing associations over time
The study by Leoutsakos et al. (2012) was the only study that used both time-invariant and
time-varying covariates, while the other studies analyzed comorbid disease burden as a base-
line, time-invariant predictor only. Analyzing comorbid disease burden as a time-varying
covariate means looking at the relationship between comorbidity and LOAD facets at
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corresponding points over time. Comparing these two analysis approaches offered an interest-
ing perspective; when analyzing the association between baseline medical health rating and
subsequent LOAD progression no significant relationship was found, however, upon examina-
tion of the rating as a time-varying covariate, a clear association with cognitive, functional and
psychiatric progression emerged [13]. Based on these results Leoutsakos et al. (2012) postu-
lated that the association between comorbid disease burden and LOAD progression is an
immediate, proximal one; how patients are doing on the facets of LOAD at a given point in
time is affected by their health at that time.
The results of this review provide support for this notion, since associations were predomi-
nantly found in studies analyzing cross-sectional associations or near future progression and
were rarely observed in studies analyzing progression in the distant future. For example, when
examining the studies on comorbidity and cognition, six out of seven studies reporting an
association measured cognition cross-sectionally or in the near future. In other words, the
time between comorbidity measurement and analyzed symptoms (from now on referred to as
‘measurement interval’) in these studies was shorter than 2 years (Table 1). For the extent to
which longitudinal studies with measurement intervals longer than 2 years were available [13,
14, 19, 22], the evidence for associations between baseline comorbidity burden and cognitive
progression was lacking. A possible explanation for this pattern could be that comorbidity sta-
tus fluctuates, which could dilute the relationship between baseline comorbid disease burden
and cognitive progression over time.
In short, the association of comorbidity and cognition appears to be time-varying, i.e.
dynamic. This hypothesis is supported by previous studies with a more specific scope of vascu-
lar co-morbidities, which found associations between change in comorbidity measures and
progression of cognitive impairment [36–38]. Using comorbidity as a time-varying covariate
could possibly elucidate the relationship with progression by taking fluctuations in comorbid-
ity status across follow-up into account. Although it is generally accepted that proving causality
is hardly possible in observational studies, it must be noted that this is particularly so in time-
varying analysis, since the establishment of a temporal relationship is impossible. Another
important methodological consequence of studying occurrence relations in a time-varying
way is that levels of exposure to possible risk factors need to be established at all follow-ups.
This predictor information may not be available at follow-up assessments or be assessed with
less rigor or detail in cohort studies.
4.3 Potential mechanisms of the effect of comorbidity
The potential mechanisms through which comorbidity may affect the different dimensions of
LOAD are numerous. For example, comorbidity is often associated with increased stress levels
and it has been shown that stressful experiences are associated with increased risk of dementia,
possibly through an imbalance in the adrenocortical axis [3]. A study in mice showed that
short stress simulating conditions may exacerbate cognitive deficits in preclinical LOAD by
accelerating amyloid pathology and reducing synapse numbers [39]. Another common feature
of comorbidity is disrupted sleep, which is known to increase the risk of cognitive impairment
[40]. Especially in people with LOAD, sleep deprivation may contribute to worse cognitive
function and more NPS, since LOAD itself is already associated with a delay in circadian phase
[41, 42]. In line with our findings, a detrimental influence of comorbidities on cognition was
also observed in people with Parkinson’s disease [43]. A prospective study including 294
elderly showed that excessive polypharmacy, a logical consequence of increased comorbid dis-
ease burden, is also associated with decreased cognitive capacity [7]. Moreover, polypharmacy
has been found to contribute to functional decline in community-dwelling patients with
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LOAD [44]. The fact that comorbid disease burden appears to be positively associated with
both cognitive and functional decline is not surprising given the two are strongly related in
LOAD [1]. In fact, functional impairment in AD appears to follow cognitive impairment tem-
porally [45, 46]. Impaired daily functioning, in turn, may decrease the amount of leisure and
social activities, which are known to be protective against cognitive decline [47], or lower levels
of other healthy behaviors and self-care. Similar mechanisms as stated in the previous para-
graph could therefore drive the patient into a negative spiral of both functional and cognitive
deterioration. A relationship between disease burden and daily functioning was also observed
in several large population-based studies in healthy elderly [48]. This indicates that comorbid
conditions may lead to functional impairment irrespective of LOAD diagnosis, for example
through conditions affecting mobility. Although the number of studies supporting an associa-
tion between comorbidities and increased NPS in LOAD is small, multiple studies in different
populations support the relation between increased comorbid disease burden and psychiatric
disorders such as anxiety and depression [8, 49]. The cognitive and functional consequences of
increased comorbid disease burden are likely to contribute to social deprivation and stress,
which were found to be significant predictors of psychosis and depression [50].
4.4 Comparability of included studies
During the critical appraisal of the studies, some methodological challenges emerged. The
divergent sampling frame was one of them. Three of the studies were population-based, while
seven used a clinical sample and one study sample was obtained in multiple settings (Table 1).
Although heterogeneity can increase external validity, differences in study setting can also
potentially influence the results due to differences in case-mix. However, comparing the popu-
lation based and non-population-based studies which analyzed similar dimensions, no pattern
of discrepancy was found in the results. Thus, the association between somatic comorbidities
and progression appears to be independent of study setting.
Differences in inclusion criteria among studies could also affect the case-mix and therefore
hinder comparability between studies. Only the study by Boksay et al. (2005) used stringent
criteria by excluding patients with history of various comorbidities, which might hamper com-
parability, along with its small sample size and lack of correction for age, education and base-
line cognitive status in its analyses.
Four studies did not analyze results for LOAD separately from other dementia types [14,
15, 20, 22]. Since all four studies reported the majority of their sample to be suffering from
LOAD and their results appeared to be in accordance with the other studies included, this
probably had only minor influence on our results.
Given the high quality of the cross-sectional studies, we decided to include both longitudi-
nal and cross-sectional studies in this review to provide an integrated overview of all available
studies on this topic. Although the cross-sectional studies do not address disease progression
over time, they were mostly in line with the longitudinal studies using measurement intervals
2 years.
4.5 Strengths and limitations
One of the strengths of this review is its multidimensional approach. As it is unambiguous that
patients also experience impairment in their activities of daily living and behavioral changes,
LOAD cannot be defined as cognitive impairment alone [4]. The narrow approach of LOAD
progression adopted in many studies is therefore worrisome. By taking into account all three
dimensions this review provides a more comprehensive perspective on LOAD.
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A limitation of this review is the large variation in progression measures, comorbidity
indexes, data sources and study designs of the included studies (Table 1), which hampers
quantification of the association between comorbid disease burden and progression. The dif-
ferences between study populations also pose a problem, given the large heterogeneity in age,
gender, stage of LOAD and medication use. Moreover, it is questionable whether all measures
of a certain dimension truly reflect the same construct or whether the comorbidity measures
were sensitive enough to capture comorbidity burden with sufficient detail. Therefore, no
meta-analysis could be performed.
Another limitation of this review is that none of its studies took the onset or duration of
comorbidities into account. It might be not so much the amount or severity of the comorbidity
burden that is relevant, but rather the length of the exposure to comorbidity burden. Without
this information, this hypothesis is impossible to be verified or refuted. Given that dementia
has a long period of insidious onset, reverse causation cannot be ruled out, not even in the
studies which focused on the effect of comorbidity burden at the point where LOAD became
incident.
In contrast to many other studies which focus on a single comorbid condition, this review
aimed to examine the relation of overall somatic comorbid disease burden with LOAD pro-
gression, providing a more generalizable overview. However, a drawback of using scales for
overall comorbid disease burden is the potential circularity in the studies examining NPS,
caused by the presence of a psychiatric domain in some of the comorbidity measures, such as
CIRS-G. The choice to study overall comorbidity burden also renders it impossible to draw
conclusions about individual comorbidities. Understanding the mechanisms of and the extent
to which singular comorbidities affect the course of LOAD might enable us to slow down mul-
tidimensional progression and provide a more individualized prognosis. However, this was
beyond the scope of this review.
4.6 Conclusion
It is evident that cognitive, functional and psychiatric decline should be addressed simulta-
neously to obtain a more comprehensive understanding of LOAD progression. One of our
first observations is that, although highly relevant, only three studies have addressed these
three dimensions of LOAD simultaneously. Therefore, additional multidimensional longitudi-
nal studies are needed to provide a scientific basis for evidence-based care of the growing num-
ber of individuals affected with LOAD and comorbid diseases.
This review provides evidence of an association between somatic comorbidities and multi-
faceted LOAD progression. Given that comorbid disease burden at a given time point seems
to be associated with LOAD facets around that same moment, while not in the long term, it
seems likely that there is a dynamic relationship between comorbid disease burden and LOAD
progression.
With comorbidity burden being a possibly modifiable factor contributing to LOAD, these
results stress the importance of optimal treatment and monitoring of comorbidities in people
with LOAD. Monitoring progression might be particularly important in case somatic comor-
bidities manifest after LOAD onset, given the association between comorbidities and LOAD
progression in the near future. Prevention and accurate treatment of comorbidities by health
care professionals may prevent rapid progression of LOAD.
Moreover, this review emphasizes the relevance of taking comorbidity burden into account
when investigating LOAD progression, not only at diagnosis, but also at follow-up. Future
studies might gain more knowledge by considering the possibility of a dynamic interconnec-
tion between comorbid disease burden and LOAD progression, by means of repeatedly
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measuring comorbidity status from the preclinical phase of LOAD onwards and analyzing it as
a time-varying covariate.
Concluding, there is a clear association between comorbid disease burden and LOAD pro-
gression and this association cannot be reduced to a simple, linear cause-effect relation. There-
fore, both future studies and clinical practice may benefit from regarding comorbidity as a
modifiable factor with a possibly fluctuating influence on LOAD.
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